SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.
This article summarized the latest R&D progress of dermatan sulfate, the Mechanism of Action for dermatan sulfate, and the drug target R&D trends for dermatan sulfate.
Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.
This article summarized the latest R&D progress of darifenacin hydrobromide, the Mechanism of Action for darifenacin hydrobromide, and the drug target R&D trends for darifenacin hydrobromide.
The most commonly used efficacy endpoints in clinical trials of anti-tumor drugs are Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS), among others.
Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.
This article summarized the latest R&D progress of cysteamine hydrochloride, the Mechanism of Action for cysteamine hydrochloride, and the drug target R&D trends for cysteamine hydrochloride.
Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.
TTF, in comparison to PFS, synthesizes the effectiveness and safety characteristics of the drug, encompasses treatment failure for any reason and includes death.
This article summarized the latest R&D progress of cyclizine hydrochloride, the Mechanism of Action for cyclizine hydrochloride, and the drug target R&D trends for cyclizine hydrochloride.
Event-Free Survival (EFS), compared to Disease-Free Survival (DFS), adds a surgical intervention criterion and is often used to evaluate neoadjuvant therapy pre-surgery, or radiotherapy.